290 related articles for article (PubMed ID: 26345211)
21. Efficacy and Safety of Mirabegron in Men with Overactive Bladder Symptoms and Benign Prostatic Hyperplasia.
Mullen GR; Kaplan SA
Curr Urol Rep; 2021 Jan; 22(1):5. PubMed ID: 33411109
[TBL] [Abstract][Full Text] [Related]
22. Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine.
Sebastianelli A; Russo GI; Kaplan SA; McVary KT; Moncada I; Gravas S; Chapple C; Morgia G; Serni S; Gacci M
Int J Urol; 2018 Mar; 25(3):196-205. PubMed ID: 29205506
[TBL] [Abstract][Full Text] [Related]
23. Mirabegron for the treatment of overactive bladder.
Gras J
Drugs Today (Barc); 2012 Jan; 48(1):25-32. PubMed ID: 22384458
[TBL] [Abstract][Full Text] [Related]
24. A quantitative benefit-risk assessment approach to improve decision making in drug development: Application of a multicriteria decision analysis model in the development of combination therapy for overactive bladder.
de Greef-van der Sandt I; Newgreen D; Schaddelee M; Dorrepaal C; Martina R; Ridder A; van Maanen R
Clin Pharmacol Ther; 2016 Apr; 99(4):442-51. PubMed ID: 26422298
[TBL] [Abstract][Full Text] [Related]
25. Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial.
Dai R; Deng C
World J Urol; 2024 May; 42(1):316. PubMed ID: 38736011
[No Abstract] [Full Text] [Related]
26. Profile of mirabegron in the treatment of overactive bladder: place in therapy.
Sharaf A; Hashim H
Drug Des Devel Ther; 2017; 11():463-467. PubMed ID: 28255232
[TBL] [Abstract][Full Text] [Related]
27. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.
Chapple CR; Kaplan SA; Mitcheson D; Klecka J; Cummings J; Drogendijk T; Dorrepaal C; Martin N
Eur Urol; 2013 Feb; 63(2):296-305. PubMed ID: 23195283
[TBL] [Abstract][Full Text] [Related]
28. A drug safety evaluation of mirabegron in the management of overactive bladder.
Robinson D; Thiagamoorthy G; Cardozo L
Expert Opin Drug Saf; 2016 May; 15(5):689-96. PubMed ID: 26980445
[TBL] [Abstract][Full Text] [Related]
29. Combination of solifenacin and mirabegron for overactive bladder management.
Cornu JN
BJU Int; 2015 Oct; 116(4):498-9. PubMed ID: 26350574
[No Abstract] [Full Text] [Related]
30. Safety and efficacy of mirabegron in daily clinical practice: a prospective observational study.
Kallner HK; Christensson AA; Elmér C; Flam B; Altman D
Eur J Obstet Gynecol Reprod Biol; 2016 Aug; 203():167-72. PubMed ID: 27318184
[TBL] [Abstract][Full Text] [Related]
31. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.
Herschorn S; Barkin J; Castro-Diaz D; Frankel JM; Espuna-Pons M; Gousse AE; Stölzel M; Martin N; Gunther A; Van Kerrebroeck P
Urology; 2013 Aug; 82(2):313-20. PubMed ID: 23769122
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
[TBL] [Abstract][Full Text] [Related]
33. Comparisons of the Clinical Outcomes and Urodynamic Effects of Mirabegron versus Tolterodine Treatment for Female Overactive Bladder Syndrome: A Subgroup Analysis of a Controlled, Randomised, Prospective Study.
Hsiao SM; Chang TC; Chen CH; Wu WY; Lin HH
Low Urin Tract Symptoms; 2018 Sep; 10(3):215-220. PubMed ID: 28436145
[TBL] [Abstract][Full Text] [Related]
34. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.
Nazir J; Maman K; Neine ME; Briquet B; Odeyemi IA; Hakimi Z; Garnham A; Aballéa S
Value Health; 2015 Sep; 18(6):783-90. PubMed ID: 26409605
[TBL] [Abstract][Full Text] [Related]
35. Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER).
Herschorn S; Staskin D; Tu LM; Fialkov J; Walsh T; Gooch K; Schermer CR
Health Qual Life Outcomes; 2018 Apr; 16(1):69. PubMed ID: 29673355
[TBL] [Abstract][Full Text] [Related]
36. Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia.
Chapple CR; Siddiqui E
Expert Rev Clin Pharmacol; 2017 Feb; 10(2):131-151. PubMed ID: 28001447
[TBL] [Abstract][Full Text] [Related]
37. Clinical efficacy and safety of mirabegron and imidafenacin in women with overactive bladder: A randomized crossover study (the MICRO study).
Torimoto K; Matsushita C; Yamada A; Goto D; Matsumoto Y; Hosokawa Y; Miyake M; Aoki K; Hirayama A; Tanaka N; Fujimoto K
Neurourol Urodyn; 2017 Apr; 36(4):1097-1103. PubMed ID: 27265880
[TBL] [Abstract][Full Text] [Related]
38. Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR).
Wagg A; Staskin D; Engel E; Herschorn S; Kristy RM; Schermer CR
Eur Urol; 2020 Feb; 77(2):211-220. PubMed ID: 31733990
[TBL] [Abstract][Full Text] [Related]
39. Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder.
Blais AS; Nadeau G; Moore K; Genois L; Bolduc S
Eur Urol; 2016 Jul; 70(1):9-13. PubMed ID: 26876327
[TBL] [Abstract][Full Text] [Related]
40. Words of Wisdom. Re: Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony).
Cruz F
Eur Urol; 2015 Jun; 67(6):1189-90. PubMed ID: 25944037
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]